Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Bibliographic Details
Main Authors: Takeharu Yamanaka, Koji Yamamoto, Yasushi Honda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Satoru Saito, Michihiro Iwaki, Yusuke Saigusa, Haruki Usuda, Koichiro Wada
Format: Article
Language:English
Published: BMJ Publishing Group 2020-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/9/e037961.full

Internet

https://bmjopen.bmj.com/content/10/9/e037961.full

Similar Items